ADC THERAPEUTICS SA 2024-2025 Proxy Voting Records

Description as filed by funds: Discharging the members of the Board of Directors and the Executive Committee from Liability for the year ended December 31, 2024 The Board of Directors proposes that the members of the Board of Directors and the Executive Committee be discharged from liability for the year ended December 31, 2024.

ADC THERAPEUTICS SA’s own tally for this item (“3. Discharging the members of the board of directors and the executive committee from liability”): 41,463,514 for, 4,933,137 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #3 : Discharging the members of the board of directors and the executive committee from liability The shareholders approved that the members of the board of directors and the executive committee be discharged from liability for the year ended December 31, 2024.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 1,572,629 for.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: Electing and reelecting nominees to the Board of Directors: The Board of Directors proposes that Ameet Mallik be reelected as a director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

ADC THERAPEUTICS SA’s own tally for this item (“Elect Director: Ameet Mallik”): 47,898,350 for, 148,970 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Electing and reelecting directors The shareholders elected or reelected, as applicable, the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of shareholders.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 1,572,629 for.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: Electing and reelecting nominees to the Board of Directors: The Board of Directors proposes that Jean-Pierre Bizzari be reelected as a director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

ADC THERAPEUTICS SA’s own tally for this item (“Elect Director: Jean-Pierre Bizzari”): 45,409,931 for, 2,615,372 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Electing and reelecting directors The shareholders elected or reelected, as applicable, the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of shareholders.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 1,152,062 for, 398,547 against, 22,020 abstained.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: Electing and reelecting nominees to the Board of Directors: The Board of Directors proposes that Ron Squarer be reelected as the chair of the Board of Directors and a director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

ADC THERAPEUTICS SA’s own tally for this item (“Elect Director: Ron Squarer”): 47,887,130 for, 160,193 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Electing and reelecting directors The shareholders elected or reelected, as applicable, the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of shareholders.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 1,565,422 for, 7,207 against.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: Electing and reelecting nominees to the Board of Directors: The Board of Directors proposes that Timothy Coughlin be elected as a director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

ADC THERAPEUTICS SA’s own tally for this item (“Elect Director: Timothy Coughlin”): 47,922,751 for, 124,670 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Electing and reelecting directors The shareholders elected or reelected, as applicable, the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of shareholders.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 1,572,629 for.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: Electing and reelecting nominees to the Board of Directors: The Board of Directors proposes that Tyrell Rivers be reelected as a director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

ADC THERAPEUTICS SA’s own tally for this item (“Elect Director: Tyrell Rivers”): 47,898,929 for, 147,892 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Electing and reelecting directors The shareholders elected or reelected, as applicable, the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of shareholders.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 1,572,629 for.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: Electing and reelecting nominees to the Board of Directors: The Board of Directors proposes that Viviane Monges be reelected as a director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

ADC THERAPEUTICS SA’s own tally for this item (“Elect Director: Viviane Monges”): 47,656,746 for, 367,800 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Electing and reelecting directors The shareholders elected or reelected, as applicable, the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of shareholders.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 1,438,666 for, 133,963 against.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: Electing and reelecting nominees to the Board of Directors: The Board of Directors proposes that Peter Hug be reelected as a director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

The 21 asset managers below reported 317,890 for, 421,611 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Electing and reelecting nominees to the Board of Directors: The Board of Directors proposes that Robert Azelby be reelected as a director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

The 21 asset managers below reported 451,853 for, 287,648 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Electing and reelecting nominees to the Board of Directors: The Board of Directors proposes that Victor Sandor be reelected as a director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

The 21 asset managers below reported 451,853 for, 287,648 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Reelecting nominees to the Compensation Committee of the Board of Directors: The Board of Directors proposes that Peter Hug be reelected as a member of the Compensation Committee for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

The 21 asset managers below reported 324,749 for, 414,752 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Reelecting nominees to the Compensation Committee of the Board of Directors: The Board of Directors proposes that Robert Azelby be reelected as a member of the Compensation Committee for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

The 21 asset managers below reported 451,853 for, 287,648 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Reelecting nominees to the Compensation Committee of the Board of Directors: The Board of Directors proposes that Victor Sandor be reelected as a member of the Compensation Committee for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

The 21 asset managers below reported 451,853 for, 287,648 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: RE-ELECTION OF NOMINEE TO THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: THE BOARD OF DIRECTORS PROPOSES THAT PETER HUG BE REELECTED AS A MEMBER OF THE COMPENSATION COMMITTEE FOR A ONE-YEAR TERM, BEGINNING AS OF THE ANNUAL MEETING AND ENDING AT THE CLOSING OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS.

The 7 asset managers below reported 833,128 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: RE-ELECTION OF NOMINEE TO THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: THE BOARD OF DIRECTORS PROPOSES THAT ROBERT AZELBY BE REELECTED AS A MEMBER OF THE COMPENSATION COMMITTEE FOR A ONE-YEAR TERM, BEGINNING AS OF THE ANNUAL MEETING AND ENDING AT THE CLOSING OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS.

The 7 asset managers below reported 833,128 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: RE-ELECTION OF NOMINEE TO THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: THE BOARD OF DIRECTORS PROPOSES THAT VICTOR SANDOR BE REELECTED AS A MEMBER OF THE COMPENSATION COMMITTEE FOR A ONE-YEAR TERM, BEGINNING AS OF THE ANNUAL MEETING AND ENDING AT THE CLOSING OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS.

The 7 asset managers below reported 833,128 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: THE BOARD OF DIRECTORS PROPOSES THAT PETER HUG BE REELECTED AS A DIRECTOR FOR A ONE-YEAR TERM, BEGINNING AS OF THE ANNUAL MEETING AND ENDING AT THE CLOSING OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS.

The 7 asset managers below reported 833,128 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: THE BOARD OF DIRECTORS PROPOSES THAT ROBERT AZELBY BE REELECTED AS A DIRECTOR FOR A ONE-YEAR TERM, BEGINNING AS OF THE ANNUAL MEETING AND ENDING AT THE CLOSING OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS.

The 7 asset managers below reported 833,128 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: THE BOARD OF DIRECTORS PROPOSES THAT VICTOR SANDOR BE REELECTED AS A DIRECTOR FOR A ONE-YEAR TERM, BEGINNING AS OF THE ANNUAL MEETING AND ENDING AT THE CLOSING OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS.

The 7 asset managers below reported 833,128 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Approving amendments to article 4b of the articles of association to increase the Company's conditional share capital for employee participation The Board of Directors is proposing that the amendments to article 4b paragraph 1 of the articles of association to increase the Company's conditional share capital for employee participation from 9,547,482 common shares (CHF 763,798.56) to 12,776,259 common shares (CHF 1,022,100.72) be approved, as follows (amendment underlined for ease of reference): "The share capital may be increased in an amount not to exceed CHF 1,022,100.72 through the issuance of up to 12,776,259 fully paid in registered shares with a par value of CHF 0.08 per share through the direct or indirect issuance of shares, or through the exercise or mandatory exercise of rights to acquire shares or through obligations to acquire shares, which were granted to or imposed on members of the Board of Directors, members of the executive management, employees, contractors or consultants of the Company or its group companies, or other persons providing services to the Company or its group companies."

ADC THERAPEUTICS SA’s own tally for this item (“12. Approving amendments to article 4b of the articles of association to increase the conditional share capital for employee participation”): 43,270,118 for, 4,680,858 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #12 : Approving amendments to article 4b of the articles of association to increase the conditional share capital for employee participation The shareholders approved amendments to article 4b of the articles of association to increase the conditional share capital for employee participatio…”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 310,016 for, 1,262,613 against.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: Approving amendments to Article 4a of the articles of association to increase the Company's capital range The Board of Directors proposes that the amendments to Article 4a of the articles of association to increase the Company's capital range be approved.

ADC THERAPEUTICS SA’s own tally for this item (“1. Approving amendments to Article 4a of the articles of association to increase the Company's capital range”): 52,359,308 for, 9,026,049 against — passed, per its Form 8-K filed November 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #1 : Approving amendments to Article 4a of the articles of association to increase the Company's capital range The shareholders approved the amendments to Article 4a of the articles of association to increase the Company's capital range.”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 27 asset managers below reported 4,985 for, 2,483,744 against.

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Description as filed by funds: Approving amendments to Article 4c of the articles of association to Increase the Company's conditional share capital for financing, acquisitions and other purposes The Board of Directors proposes that the amendments to Article 4c of the articles of association to increase the Company's conditional share capital for financing, acquisitions and other purposes be approved.

ADC THERAPEUTICS SA’s own tally for this item (“2. Approving amendments to Article 4c of the articles of association to increase the Company's conditional share capital for financing, acquisitions and other purposes”): 52,348,342 for, 9,041,603 against — passed, per its Form 8-K filed November 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #2 : Approving amendments to Article 4c of the articles of association to increase the Company's conditional share capital for financing, acquisitions and other purposes The shareholders approved the amendments to Article 4c of the articles of association to increase the Company's conditio…”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 27 asset managers below reported 4,985 for, 2,483,744 against.

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Description as filed by funds: Approving the appropriation of the financial results for the year ended December 31, 2024, by carrying forward the loss resulting from such year The board of directors proposes that the net loss for the year ended December 31, 2024, be carried forward as follows: Loss carried forward from the year ended December 31,2023 CHF 1,113,390,115 Loss for the year ended December 31, 2024 CHF 93,463,700 Loss to be carried forward CHF 1,206,853,815

ADC THERAPEUTICS SA’s own tally for this item (“4. Approving the appropriation of the financial results”): 60,287,802 for, 194,334 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #4 : Approving the appropriation of the financial results The shareholders approved that the net loss for the year ended December 31, 2024 be carried forward.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 1,572,629 for.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: Reelecting PHC Notaires, in Lausanne, Switzerland, as the Independent Proxy The Board of Directors proposes that PHC Notaires, in Lausanne, Switzerland, be reelected as the Independent Proxy for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of Shareholders.

ADC THERAPEUTICS SA’s own tally for this item (“7. Reelecting the Independent Proxy”): 60,221,310 for, 276,435 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 1,572,629 for.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: If a new proposal is made under a new or existing agenda item, I instruct the independent proxy to:

The 22 asset managers below reported 816,261 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

The 21 asset managers below reported 739,501 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan The Board of Directors is proposing that an amendment to increase the number of shares authorized under 2019 Equity Incentive Plan be approved.

ADC THERAPEUTICS SA’s own tally for this item (“11. Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan”): 42,802,737 for, 5,226,105 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #11 : Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan The shareholders approved an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 348 for, 1,572,281 against.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: The Board of Directors proposes that the maximum aggregate amount of variable compensation for the members of the Executive Committee for the year ending December 31, 2025, be set at $3,500,000.

The 21 asset managers below reported 739,501 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: APPROVING, ON A BINDING BASIS UNDER SWISS LAW, THE COMPENSATION OF THE BOARD OF DIRECTORS AND THE EXECUTIVE COMMITTEE: THE BOARD OF DIRECTORS PROPOSES THAT THE MAXIMUM AGGREGATE AMOUNT OF VARIABLE COMPENSATION FOR THE MEMBERS OF THE EXECUTIVE COMMITTEE FOR THE YEAR ENDING DECEMBER 31, 2025, BE SET AT $3,500,000.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 7 managers: 833,128 for.

Institutional-manager reports, all 3 managers: 226,429 for.

Description as filed by funds: Approving, on an advisory basis under U.S. law, the compensation paid to our Named Executive Officers The Board of Directors is proposing that the following proposal: "RESOLVED, that the Company's Shareholders approve, on an advisory basis under U.S. law, the compensation of the Company's Named Executive Officers, as disclosed in "Executive Compensation" and the related compensation tables and narrative disclosure in this proxy statement", be approved.

ADC THERAPEUTICS SA’s own tally for this item (“10. Approving, on an advisory basis under U.S. law, the compensation paid to the named executive officers”): 47,645,306 for, 303,251 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #10 : Approving, on an advisory basis under U.S. law, the compensation paid to the named executive officers The shareholders approved, on an advisory basis under U.S. law, the compensation of the Company's named executive officers, as disclosed in "Executive Compensation" and the related c…”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 28 managers: 1,572,629 for. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports, all 69 managers: 31,638,773 for, 17,440 against, 6,139,067 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Description as filed by funds: Approving, on an advisory basis under Swiss law, the Company's Compensation Report for the year ended December 31, 2024 The Board of Directors proposes that the Company's Compensation report for the year ended December 31, 2024, be approved in a non-binding advisory vote.

ADC THERAPEUTICS SA’s own tally for this item (“2. Approving, on an advisory basis under Swiss law, the compensation report”): 47,765,084 for, 190,266 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #2 : Approving, on an advisory basis under Swiss law, the compensation report The shareholders approved, in a non-binding advisory vote, the compensation report for the year ended December 31, 2024.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 28 managers: 1,572,629 for. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports, all 6 managers: 1,785,041 for.

Description as filed by funds: Approving, on a binding basis under Swiss law, the compensation of the Board of Directors and the Executive Committee The Board of Directors proposes that the maximum aggregate amount of compensation for the members of the Board of Directors for the period between the Annual Meeting and the 2026 annual general meeting of Shareholders be set at $2,300,000.

The 30 asset managers below reported 10,822 for, 1,564,155 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

Description as filed by funds: The Board of Directors proposes that the maximum aggregate amount of fixed compensation for the members of the Executive Committee for the year ending December 31, 2026, be set at $2,600,000.

The 21 asset managers below reported 739,501 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: APPROVING, ON A BINDING BASIS UNDER SWISS LAW, THE COMPENSATION OF THE BOARD OF DIRECTORS AND THE EXECUTIVE COMMITTEE: THE BOARD OF DIRECTORS PROPOSES THAT THE MAXIMUM AGGREGATE AMOUNT OF FIXED COMPENSATION FOR THE MEMBERS OF THE EXECUTIVE COMMITTEE FOR THE YEAR ENDING DECEMBER 31, 2026, BE SET AT $2,600,000.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 7 managers: 833,128 for.

Institutional-manager reports, all 3 managers: 226,429 for.

Description as filed by funds: Approving the Company's Management Report, Annual Financial Statements and Consolidated Financial Statements for the year ended December 31, 2024, and acknowledging the Auditors' Reports for the year ended December 31, 2024 The Board of Directors proposes that the Management Report, the Annual Financial Statements and the Consolidated Financial Statements for the year ended December 31, 2024, be approved and the Auditors' Reports for the year ended December 31, 2024, be acknowledged.

ADC THERAPEUTICS SA’s own tally for this item (“1. Approving the management report, annual financial statements and consolidated financial statements”): 60,305,481 for, 175,719 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #1 : Approving the management report, annual financial statements and consolidated financial statements The shareholders approved the management report, the annual financial statements and the consolidated financial statements for the year ended December 31, 2024 and acknowledged the audit…”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 1,572,629 for.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: Reelecting PricewaterhouseCoopers SA as the auditors The Board of Directors proposes that PricewaterhouseCoopers SA be reelected as the statutory auditor and independent registered public accounting firm for the year ending December 31, 2025.

ADC THERAPEUTICS SA’s own tally for this item (“8. Reelecting the auditors”): 60,360,349 for, 71,384 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 1,572,629 for.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).